SG11201810308TA - Oral tipepidine preparation - Google Patents

Oral tipepidine preparation

Info

Publication number
SG11201810308TA
SG11201810308TA SG11201810308TA SG11201810308TA SG11201810308TA SG 11201810308T A SG11201810308T A SG 11201810308TA SG 11201810308T A SG11201810308T A SG 11201810308TA SG 11201810308T A SG11201810308T A SG 11201810308TA SG 11201810308T A SG11201810308T A SG 11201810308TA
Authority
SG
Singapore
Prior art keywords
tipepidine
oral
preparation
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
SG11201810308TA
Inventor
Naomi Esaki
Kyoko Kawada
Kazuki Morizaki
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of SG11201810308TA publication Critical patent/SG11201810308TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

ORAL TIPEPIDINE PREPARATION In the present invention, the drug dissolution rate of tipepidine or a pharmaceutically acceptable salt thereof is controlled to thereby provide a new oral composition of once- or twice-a-day dosage type comprising tipepidine or a pharmaceutically acceptable salt thereof. FIG. 10
SG11201810308TA 2016-05-30 2017-05-30 Oral tipepidine preparation SG11201810308TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016107387 2016-05-30
PCT/JP2017/020038 WO2017209106A1 (en) 2016-05-30 2017-05-30 Oral tipepidine preparation

Publications (1)

Publication Number Publication Date
SG11201810308TA true SG11201810308TA (en) 2018-12-28

Family

ID=60478572

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201810308TA SG11201810308TA (en) 2016-05-30 2017-05-30 Oral tipepidine preparation

Country Status (6)

Country Link
JP (1) JP6380922B2 (en)
KR (1) KR20180137566A (en)
PH (1) PH12018502490A1 (en)
SG (1) SG11201810308TA (en)
TW (1) TW201803564A (en)
WO (1) WO2017209106A1 (en)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0759521B2 (en) * 1985-09-30 1995-06-28 藤沢薬品工業株式会社 Gel layer-forming sustained-release preparation
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
JPH05255125A (en) * 1992-02-29 1993-10-05 Upjohn Co:The Sustained release preparation and its preparation
JPH1017497A (en) * 1996-07-02 1998-01-20 Takeda Chem Ind Ltd Sustained release pharmaceutical preparation and its production
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
JP5850299B2 (en) * 2010-04-28 2016-02-03 国立大学法人 熊本大学 Obsessive-compulsive disorder treatment
JP6032561B2 (en) * 2011-03-03 2016-11-30 国立大学法人 熊本大学 Drugs that improve central function in pain
JP5858477B2 (en) * 2011-09-01 2016-02-10 国立大学法人 熊本大学 Drugs for negative symptoms of schizophrenia
CN113384546A (en) * 2012-11-15 2021-09-14 因赛特公司 Sustained release dosage forms of ruxolitinib

Also Published As

Publication number Publication date
WO2017209106A1 (en) 2017-12-07
KR20180137566A (en) 2018-12-27
TW201803564A (en) 2018-02-01
PH12018502490A1 (en) 2019-09-30
JPWO2017209106A1 (en) 2018-07-19
JP6380922B2 (en) 2018-08-29

Similar Documents

Publication Publication Date Title
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
PH12016501310A1 (en) Pharmaceutical compositions comprising azd9291
EA201792592A1 (en) PHARMACEUTICAL PREPARATIONS CONTAINING TENOFOVIR AND EMTRICITABIN
EA201992116A1 (en) PHARMACEUTICAL COMPOSITIONS OF FLOROGLUCINOL AND TRIMETHYLFLOROGLUCINOL
MX2020012978A (en) Pharmaceutically acceptable salts of sepiapterin.
SG11201808607SA (en) Medicine obtained by combining fxr agonist and arb
EA201792591A1 (en) PHARMACEUTICAL PREPARATIONS
EA201691789A1 (en) PHARMACEUTICAL COMPOSITIONS AND SALTS OF 1,2,4-OXADIAZOLBENZOIC ACID
MX2020007552A (en) Stable pharmaceutical composition comprising esomeprazole and sodium bicarbonate.
MA39765A (en) Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use
MX2018000084A (en) Pharmaceutical composition containing amlodipine, valsartan, and rosuvastatin.
MX2016014696A (en) Combinations of formoterol and budesonide for the treatment of copd.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
PH12017500536A1 (en) Solid pharmaceutical composition comprising amlodipine and losartan
EA201892842A1 (en) PHARMACEUTICAL COMPOSITIONS, INCLUDING SAFINAMID
MX2018014184A (en) Triple combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonist.
SG11201810308TA (en) Oral tipepidine preparation
EA201991286A1 (en) A SOLID PHARMACEUTICAL COMPOSITION FOR ORAL USE CONTAINING TENOFOVIR AND EMTRITSITABIN
PH12017501736A1 (en) Indole derivatives
PH12016502527B1 (en) Stabilized desmopressin
MX2017014725A (en) Dropropizine in combination with ambroxol in the dosage form of syrup or tablets.
TR201722852A2 (en) Oral pharmaceutical compositions of mesalazine
MX2018007272A (en) Pulsatile release pharmaceutical composition comprising naftazone or one of its salts.
EA201891911A1 (en) APPLICATION OF TAMOXIFEN FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS OF BOTH FLOORS
MX2014008984A (en) Obtention process and pharmaceutical composition of capsules of fenofibrate as a lipid regulator of oral administration.